Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Dapagliflozin may improve RAAS markers in diabetes patients
Last updated June 17, 2026
Key finding
REN levels increased significantly from baseline at 1-month visit (4.15 ± 7.35 vs. 2.75 ± 8.03 ng/L; DKD vs. non-DKD; between-group difference, p < 0.05).
This study investigated the effects of dapagliflozin on the renin-angiotensin-aldosterone system in patients with type 2 diabetes, finding significant changes in several metabolic parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Cohort
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of dapagliflozin on the renin-angiotensin-aldosterone system in patients with type 2 diabetes, finding significant changes in several metabolic parameters.
Clinical relevance
These findings suggest that dapagliflozin can effectively manage key metabolic issues in type 2 diabetes, potentially leading to better overall health outcomes. Understanding its impact on the renin-angiotensin-aldosterone system is crucial for assessing cardiovascular risks in these patients.
Keep in mind
Unclear effectiveness for some outcomes Limited generalizability due to specific population characteristics Short follow-up period may not capture long-term effects
Published in
Journal Reference
Publication details and source links for this paper.
Ningning W, Junfeng K, Ziming L, et al. The effects of dapagliflozin on the renin-angiotensin-aldosterone system in patients with type 2 diabetes and hypertension. PLOS One. 2025;20(11):e0336158. doi:10.1371/journal.pone.0336158
Main Effects
Renin levels increased significantly from baseline at 1-month visit (4.15 ng/L, p < 0.05)
BMI decreased by 0.87 kg/m²
HbA1c decreased by 1.62%
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dapagliflozin and BMI, Diastolic blood pressure, Fasting blood sugar (FBS), and 8 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
- BMI
- Diastolic blood pressure
- Fasting blood sugar (FBS)
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
11
Evidence pairs
11
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
11
Evidence pairs
841
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 11 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
SGLT2 Inhibitors and HbA1c
Related evidence
Evidence relationship
SGLT2 Inhibitors and Kidney Function
Save evidence
Evidence relationship
SGLT2 Inhibitors and Fasting Glucose
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Diastolic blood pressure
Dapagliflozin → Diastolic blood pressure
Dapagliflozin → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting blood sugar (FBS)
Dapagliflozin → Fasting blood sugar (FBS)
Dapagliflozin → Fasting blood sugar (FBS)
Evidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 6 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSystolic blood pressure
Dapagliflozin → Systolic blood pressure
Dapagliflozin → Systolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 47
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 63
- Moderate
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerUrinary albumin-to-creatinine ratio
Dapagliflozin → Urinary albumin-to-creatinine ratio
Dapagliflozin → Urinary albumin-to-creatinine ratio
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Renin increased by 4.15 ng/L, indicating hormonal changes
- BMI decreased by 0.87 kg/m², showing weight loss
- HbA1c decreased by 1.62%, reflecting better blood sugar control
Who this applies to
- Adults diagnosed with type 2 diabetes
- Patients undergoing treatment with dapagliflozin
Keep in Mind
- Results may not apply to non-diabetic populations
- Further studies needed to assess long-term effects
- Potential implications for cardiovascular risk management
Between the Lines
- Unclear effectiveness for some outcomes
- Limited generalizability due to specific population characteristics
- Short follow-up period may not capture long-term effects
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Mass Index.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 6 studies
View evidenceMedications
SGLT2 Inhibitors → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
SGLT2 Inhibitors → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
6 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
6 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
3 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
3 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dapagliflozin and HbA1c
Intervention: DapagliflozinOutcome: HbA1c
6 results
All studies on Dapagliflozin and BMI
Intervention: DapagliflozinOutcome: BMI
3 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
6 results
All studies measuring HbA1c
Outcome: HbA1c
6 results
All studies measuring BMI
Outcome: BMI
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve kidney function?
Strong Evidence
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Urinary albumin-to-creatinine ratio
EvidenceScore™ Moderate | EvidenceScore™ 73.1 | strong positive | ConsistencyScore™ Consistent | 1 study
- 2
Serum creatinine
EvidenceScore™ Emerging | EvidenceScore™ 46.9 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve fasting glucose?
Strong Evidence
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 46.9 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve adipokine and angiogenic markers?
Strong Evidence
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 63.1 | moderate positive | ConsistencyScore™ Consistent | 1 study
- 2
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 46.9 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Dapagliflozin improves metabolic outcomes in type 2 diabetes patientsMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsNatural products may improve glycemic control in type 2 diabetesDapagliflozin shows no long-term harm to bone health in women with diabetesWeight Loss Methods Improve Insulin Resistance in Type 2 Diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.